SOURCE: INSYS Therapeutics

Insys Therapeutics

November 19, 2014 16:30 ET

Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference

PHOENIX, AZ--(Marketwired - Nov 19, 2014) -  Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:

Conference: Wednesday, December 3, 2014
Time: 11:30 a.m. EST
Location: The New York Palace, New York City

The presentation will be webcast live at the aforementioned time and simultaneously available via the link provided, as well as archived for 90 days thereafter, via the Company's website at www.insysrx.com, under the Investors Section.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The Company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. Insys is also developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.